

Amoéba: publication of a scientific article concerning the efficacy of its biocontrol products to fight potato late blight

Chassieu (France), October 18 2022 – 5.45 pm - AMOÉBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the publication of a second scientific article on its biocontrol application (<https://www.mdpi.com/2223-7747/11/20/2756/pdf>) in the special issue « Plant Bioprotection » de *Plants*, journal of the MDPI Group, peer-reviewed.

This paper presents, for the first time to the international scientific community, the efficacy of the biocontrol products based on the lysate of the amoeba *Willaertia magna* C2c Maky on potato late blight. Scientific data demonstrating the dual mode of action of the lysate to control potato late blight are presented:

- the indirect effect via the stimulation of the plant's natural defences
- the direct anti-germinative effect against the pathogen, *Phytophthora infestans*, responsible for potato late blight.

The data, collected in trials carried out by independent service providers, that have demonstrated efficiency in greenhouses and in the field (2020 and 2021 seasons), are also published. **They show that lysate of the amoeba *Willaertia magna* C2c Maky, a product of natural origin, protects plant without additional treatment up to 77% when the disease was low (28% of the surface of the untreated plants affected) and up to 49% when the untreated plants were destroyed at 100%. A yield increase was also obtained with up to 30% more tubers.**

*« This second scientific paper in the frame of plant protection area, dealing with the efficacy of our biocontrol solution against potato late blight, is part of an ongoing effort to increase scientific knowledge on the amoeba *Willaertia magna* C2c Maky. It confirms its strong potential as a plant protection agent. We are continuing R&D operations and tests on other crops, the results of which will also be the subject of new publications, » says Dr Sandrine Troussieux, chief scientific officer at Amoéba.*

About AMOÉBA:

Founded in 2010, Amoéba is a French company, based in Chassieu (Lyon, France), specialised in the treatment of microbiological risk in natural resources. Over the last ten years, Amoéba has developed a triple scientific, industrial and commercial expertise around the amoeba *Willaertia magna* C2c Maky. This biological solution is an alternative to the chemical products widely used today. Amoéba is currently focusing on the biocontrol market for plant protection, estimated at €1.6 billion ⁽¹⁾, as well as on the US market for industrial water treatment in closed circuits. In the long term, the Company plans to develop new applications such as the treatment of chronic wounds, valued at €751 million ⁽²⁾ in the

United States. The commercialization of crop protection, biocides and healthcare products is subject to local regulatory approvals. The company is currently testing the biocontrol application for plant protection and does not market any products. Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. More information on www.amoeba-nature.com.

⁽¹⁾ *marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End User - Global Forecast to 2021," 2016.*

⁽²⁾ *Données Amoéba*

Contacts:

Amoéba

Valérie FILIATRE

Deputy General Manager

+33 4 26 69 16 00

valerie.filiatre@amoeba-biocide.com

Calyptus

Investor & Press Relations

Nicolas HELIN / Mathieu CALLEUX

+33 1 53 65 37 90 /91

amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 12, 2022 under number D22-0280 and available on the AMOÉBA website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.